California State Teachers Retirement System Sells 7,601 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

California State Teachers Retirement System reduced its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,445 shares of the company’s stock after selling 7,601 shares during the period. California State Teachers Retirement System owned 0.11% of Teva Pharmaceutical Industries worth $12,595,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TEVA. FMR LLC grew its position in shares of Teva Pharmaceutical Industries by 3,553.8% in the third quarter. FMR LLC now owns 2,564,339 shares of the company’s stock valued at $26,156,000 after purchasing an additional 2,494,156 shares during the last quarter. Meitav Investment House Ltd. grew its position in shares of Teva Pharmaceutical Industries by 82.8% in the fourth quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock valued at $44,914,000 after purchasing an additional 1,950,500 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after purchasing an additional 1,860,000 shares during the last quarter. AustralianSuper Pty Ltd grew its position in shares of Teva Pharmaceutical Industries by 18.8% in the fourth quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock valued at $94,368,000 after purchasing an additional 1,431,671 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $14,376,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Up 1.3 %

NYSE TEVA opened at $16.83 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The stock’s 50 day moving average is $15.02 and its two-hundred day moving average is $12.91. Teva Pharmaceutical Industries Limited has a 1-year low of $7.27 and a 1-year high of $17.39.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The company had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.3 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the transaction, the chief accounting officer now owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the transaction, the chief accounting officer now owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TEVA shares. Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price target (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Bank of America raised their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Barclays lifted their target price on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.88.

View Our Latest Stock Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.